{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:08:52Z","timestamp":1775034532368,"version":"3.50.1"},"reference-count":25,"publisher":"SLACK, Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Surg Lasers Imaging Retina"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND AND OBJECTIVE:<\/jats:title>\n                    <jats:p>To study the safety and efficacy of intravitreal injections of ziv-aflibercept (IVI-ZA) (Zaltrap; Sanofi-Aventis and Regeneron Pharmaceuticals, Tarrytown, NY) during a period of 48 weeks in patients with diabetic macular edema (DME).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS:<\/jats:title>\n                    <jats:p>Seven consecutive patients with DME were enrolled and submitted to 12 consecutive IVI-ZA with a 4-week interval. The safety parameters included changes in full-field electroretinogram (ERG) and systemic or ocular complications, and the efficacy parameters were the mean change from baseline in best-corrected visual acuity (BCVA) and central retinal thickness (CRT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      No significant differences were found in any ERG component after IVI-ZA, and no systemic or ocular complication was observed. The improvement of BCVA was most significant after the first IVI-ZA and remained until week 48 (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; .05). The CRT significantly decreased during the course of 48 weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>The 48-week results are consistent with our previous 24-week findings, supporting IVI-ZA as a safe, efficient, and well-tolerated therapy for patients with DME.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        [\n                        <jats:italic>Ophthalmic Surg Lasers Imaging Retina<\/jats:italic>\n                        . 2018;49:245\u2013250.]\n                      <\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3928\/23258160-20180329-06","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T13:13:25Z","timestamp":1523970805000},"page":"245-250","source":"Crossref","is-referenced-by-count":21,"title":["Intravitreal Ziv-Aflibercept for Diabetic Macular Edema: 48-Week Outcomes"],"prefix":"10.3928","volume":"49","author":[{"given":"Gabriel Costa","family":"de Andrade","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Rafael","family":"de Oliveira Dias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Maia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel Eid","family":"Farah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten H.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Buchele","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2012.01.004"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.10.016"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.482503"},{"issue":"7","key":"e_1_3_1_5_2","first-page":"761","article-title":"Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group","volume":"94","author":"No authors listed","year":"1987","unstructured":"No authors listed. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1987;94(7):761\u2013774.","journal-title":"Ophthalmology"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.04.024"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.06.068"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062655"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.03.045"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.12.034"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181884f2d"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414264"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001000"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-016-0026-y"},{"key":"e_1_3_1_16_2","first-page":"1315","article-title":"Molecularly targeted drugs for metastatic colorectal cancer","volume":"7","author":"Cheng YD","year":"2013","unstructured":"Cheng YD, Yang H, Chen GQ, Zhang ZC. Molecularly targeted drugs for metastatic colorectal cancer. Drug Des Devel Ther. 2013;7:1315\u20131322.","journal-title":"Drug Des Devel Ther"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20141118-15"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10633-014-9473-7"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-9762"},{"key":"e_1_3_1_20_2","first-page":"537","article-title":"Perifoveal vitreous detachment and its macular complications","volume":"103","author":"Johnson MW","year":"2005","unstructured":"Johnson MW. Perifoveal vitreous detachment and its macular complications. Trans Am Ophthalmol Soc. 2005;103:537\u2013567.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.12.039"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.02.010"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.06.017"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(99)00063-6"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.69.4.240"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10633-007-9090-9"}],"container-title":["Ophthalmic Surgery, Lasers and Imaging Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.healio.com\/doiresolver?doi=10.3928\/23258160-20180329-06","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T18:51:52Z","timestamp":1683053512000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/23258160-20180329-06"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.3928\/23258160-20180329-06"],"URL":"https:\/\/doi.org\/10.3928\/23258160-20180329-06","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736297811.793563442","asserted-by":"object"}]},"ISSN":["2325-8160","2325-8179"],"issn-type":[{"value":"2325-8160","type":"print"},{"value":"2325-8179","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}